Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on LinkedIn:
“With ASCO25 wrapping up, I wanted to acknowledge the impact of a person that- between leading the incredibly successful Dana-Farber Cancer Institute Breast Oncology division, caring for hundreds of patients with breast cancer, mentoring countless physicians around the world (including me), parenting 2 teenage daughters – also led two phase 3 trials (DESTINY-Breast09 and ASCENT-04) that will impact lives for thousands of patients globally.
Congrats Sara Tolaney!”
More posts featuring Sara Tolaney on OncoDaily.